

Iris Grossman, PhD

Chief Therapeutics Officer, Eleven Therapeutics

A science-anchored business leader with >20 years' experience on the leading edge of Personalized Medicine, Translational R&D and BioPharmaceutical Strategy. Her career achievements include numerous innovative pipelines; successful fundraising (biotech) and management of large global annual budgets (Big Pharma); extensive BoD experience; deal sheet of diverse strategic collaborations and licensing deals; as well as end-to-end portfolio strategy setting of all manners of modalities and therapeutic areas. Iris has co-founded and/or served as an Executive Operator in several cutting-edge therapeutic companies, including her current role as the Chief Therapeutics Officer at Eleven Therapeutics, where she oversees a pipeline of next generation xRNA™ programs, as well as the Business Development portfolio of the company. Prior to joining Eleven, Iris served as Chief Scientific Officer at CAMP4 and Amide Technologies, and consulted for top VCs in the Boston area. Prior to that, Dr. Grossman held leadership positions in, or consulted for Big Pharma, including GSK, Eli Lilly, Takeda and Teva – where she rose to the position of VP, Head of Early-Stage Development.

Dr. Grossman is a Strategic and/or Founding Advisor at Modulight.bio, Zelig Therapeutics and 8400 Healthcare network, serves as Board Director of the Museum of Medicine and BioMedical Discovery, and co-Chairs Boston's Executive Women In Bio (eWIB) chapter. Previously, she was the Chairperson of the Pharma/Life Sciences SAB at BC Platforms, and co-pioneered the Tipa Biobank. Furthermore, Iris won multiple awards throughout her career, including the prestigious Top 40 under 40 award (2013) by Israel's Globes.

Dr. Grossman earned her B.Sc. in Medicine at the Technion, and her Ph.D. in Medicine, Population Genomics and Pharmacogenetics at the Technion, pursued at the Weizmann Institute. Her post-doc fellowship in Personalized Medicine and Population Genomics was practiced at Duke university. She recently completed both an Executive HealthTech program at the Harvard Business School, and a Board-Room Ready certification course with eWIB at Georgetown University.